A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
- Registration Number
- NCT03085095
- Lead Sponsor
- Myovant Sciences GmbH
- Brief Summary
The purpose of this study is to determine the efficacy and safety of relugolix 120 milligrams (mg) orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (\< 50 nanograms/deciliter \[ng/dL\]) in participants with androgen-sensitive advanced prostate cancer.
- Detailed Description
This is a phase 3, multinational, randomized, open-label, parallel group study to evaluate the efficacy and safety of oral daily relugolix 120 mg in participants with androgen-sensitive advanced prostate cancer who require at least 1 year of continuous androgen-deprivation therapy. Relugolix 120 mg orally once daily or leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan and Taiwan based on local labels), every 3 months by subcutaneous injection will be administered to participants.
There are 2 analyses for this study, a primary analysis and a final analysis.
Primary Analysis:
The primary analysis of efficacy and safety has been completed (N=934). Participants were randomized 2:1 to receive relugolix or leuprolide for 48 weeks, followed by a 30-day safety follow-up visit or early termination 30-day safety follow-up.
Final Analysis:
The final analysis will occur after additional participants with metastatic disease (approximately 130) have been enrolled and randomized from any sites to the study, and have completed the 48-week treatment period. A cohort of participants enrolled in China and Taiwan will be analyzed separately once they have completed treatment to support registration in China.
Eligible participants were randomized 2:1 to relugolix or leuprolide arm and will attend visits monthly (every 4 weeks) where serum testosterone and prostate-specific antigen will be assessed. Safety will be assessed throughout the study by monitoring adverse events, vital signs, physical examinations, clinical laboratory tests, and 12-lead electrocardiograms.
Castration resistance-free survival will be assessed up to Week 49, Day 1 of the study and reported as part of the final analysis.
The study enrolled 1134 participants, including 139 participants with metastatic advanced prostate cancer to support the analysis of the secondary endpoint of castration resistance-free survival and 93 Chinese participants (enrolled in China and Taiwan) to support registration in China.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 1134
-
Has histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate.
-
Is a candidate for, in the opinion of the investigator, at least 1 year of continuous androgen deprivation therapy for the management of androgen-sensitive advanced prostate cancer with 1 of the following clinical disease state presentations:
- Evidence of biochemical (PSA) or clinical relapse following local primary intervention with curative intent, such as surgery, radiation therapy, cryotherapy, or high-frequency ultrasound and not a candidate for salvage treatment by surgery; or
- Newly diagnosed androgen-sensitive metastatic disease; or
- Advanced localized disease unlikely to be cured by local primary intervention with either surgery or radiation with curative intent.
-
Has a serum testosterone at the Screening visit of ≥ 150 ng/dL (5.2 nanomoles [nmol]/liter [L]).
-
Has a serum PSA concentration at the Screening visit of > 2.0 ng/milliliter (mL) (2.0 microgram [μg]/L), or, when applicable, post radical prostatectomy of > 0.2 ng/mL (0.2 μg/L) or post radiotherapy, cryotherapy, or high frequency ultrasound > 2.0 ng/mL (2.0 μg/L) above the post interventional nadir.
-
Has an Eastern Cooperative Oncology Group performance status of 0 or 1 at initial screening and at baseline.
Key
- In the investigator's opinion, is likely to require chemotherapy or surgical therapy for symptomatic disease management within 2 months of initiating androgen deprivation therapy.
- Previously received gonadotropin-releasing hormone analog or other form of androgen deprivation therapy (estrogen or antiandrogen) for > 18 months total duration. If androgen deprivation therapy was received for ≤ 18 months total duration, then that therapy must have been completed at least 3 months prior to baseline. If the dosing interval of the depot is longer than 3 months, then the prior androgen deprivation therapy must have been completed at least as long as the dosing interval of the depot.
- Previous systemic cytotoxic treatment for prostate cancer (for example, taxane-based regimen).
- Metastases to brain per prior clinical evaluation.
- Participants with myocardial infarction, unstable symptomatic ischemic heart disease, cerebrovascular events, or any significant cardiac condition within the prior 6 months.
- Active conduction system abnormalities.
- Uncontrolled hypertension.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Leuprolide Acetate Leuprolide Acetate Leuprolide acetate for 48 weeks Relugolix Relugolix Relugolix for 48 weeks
- Primary Outcome Measures
Name Time Method Sustained Castration Rate From Week 5 Day 1 (Day 29) to Week 49 Day 1 (Day 337) Sustained castration rate defined as the cumulative probability of testosterone suppression to \< 50 nanogram (ng)/deciliter (dL). The rate was estimated for each treatment group using the Kaplan-Meier method and reported as percentage of participants.
The lower bound of the 95% confidence interval (CI) for the cumulative probability of sustained testosterone suppression in the relugolix treatment group must have been ≥ 90% to meet evaluation criteria for efficacy.
- Secondary Outcome Measures
Name Time Method Change From Baseline In QoL Total Score As Assessed By The EORTC-QLQ-PR25 Sexual Activity And Functioning And Hormonal-Treatment-Related Symptom Subdomains Baseline, Week 49 Day 1 (Day 337) Subscales for assessment of hormonal treatment-related symptoms (6 items) and sexual activity and function (6 items) from the EORTC-QLQ-PR25 25-item prostate cancer module of the EORTC are presented. Questions used 4 point scale (1 'Not at all' to 4 'Very much'). All raw domain scores are linearly transformed to a 0-100 scale. An increase in activity or functioning scores indicates improvement (higher/healthier level of functioning) and a decrease in symptom scores indicates improvement (lower level of symptoms/problems).
Change From Baseline In QoL Total Score As Assessed By The European Quality Of Life 5-Dimension 5-Level Questionnaire (EuroQoL EQ-5D-5L) Baseline, Week 49 Day 1 (Day 337) The EuroQoL EQ-5D-5L comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 5 levels: no problems (1 as numerical score), slight problems (2 as numerical score), moderate problems (3 as numerical score), severe problems (4 as numerical score), and extreme problems (5 as numerical score). The total score ranges from 0 to 100. A decrease in score indicates improvement.
Percent Change From Baseline In Serum Concentrations Of FSH Week 1 Day 4 (Day 4), Week 5 Day 1 (Day 29), Week 25 Day 1 (Day 169), and Week 49 Day 1 (Day 337) Blood samples were collected from participants for hormonal measurements.
Percent Change From Baseline In Serum Concentrations Of Sex Hormone-Binding Globulin Week 5 Day 1 (Day 29), Week 25 Day 1 (Day 169), and Week 49 Day 1 (Day 337) Blood samples were collected from participants for hormonal measurements.
Maximum Observed Plasma Concentration (Cmax) Of Relugolix Predose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hours postdose on Day 1 and Week 2 The Cmax of relugolix was determined for single and repeat doses in subsets of participants from Japan. Single dose pharmacokinetics (PK) was assessed on Day 1 following an initial 360 mg dose of relugolix. Repeat dose PK was assessed following repeat dosing of relugolix 120 mg once daily for 2 weeks.
Profound Castration Rate At Week 3 Day 1 (Day 15) Week 3 Day 1 (Day 15) Castration rate defined as the cumulative probability of testosterone suppression to \< 20 ng/dL. The rate was estimated for each treatment group using the Kaplan-Meier method and reported as percentage of participants.
PSA Response Rate At Week 3 Day 1 Week 3 Day 1 (Day 15) PSA response defined as \> 50% reduction in PSA from baseline. The rate was estimated for each treatment group using the Kaplan-Meier method and reported as percentage of participants.
PSA Response Rate At Week 5 Day 1 Week 5 Day 1 (Day 29) PSA response defined as \> 50% reduction in PSA from baseline. The rate was estimated for each treatment group using the Kaplan-Meier method and reported as percentage of participants.
Testosterone Recovery Rate Day 90 follow-up The cumulative probability of testosterone recovery back to \> 280 ng/dL (lower limit of the normal range), back to ≥ 50 ng/dL (definition of castration), and back to \> 280 ng/dL or baseline at 90 days after drug discontinuation was assessed. The rate was estimated for each treatment group using the Kaplan-Meier method and reported as percentage of participants.
Sustained Profound Castration Rate From Week 5 Day 1 Through Week 49 Day 1 Week 5 Day 1 (Day 29) through Week 49 Day 1 (Day 337) Sustained profound castration rate was defined as the cumulative probability of testosterone suppression to \< 20 ng/dL. The rate was estimated by the Kaplan-Meier method and reported as percentage of participants.
Undetectable PSA Rate Week 25 Day 1 (Day 169) Defined as the proportion of participants with PSA concentration \< 0.02 ng/milliliter (mL).The rate was estimated by the Kaplan-Meier method and reported as percentage of participants.
Rate Of PSA Progression-free Survival Week 49 Day 1 (Day 337) PSA progression was defined as the first increase in PSA of 25% or greater and 2 ng/mL or greater above the nadir with confirmation by a second consecutive PSA measurement at least 3 weeks later. For participants without declining PSA from baseline, a PSA increase of ≥ 25% and ≥ 2 ng/mL from baseline beyond 12 weeks was considered PSA progression. The rate of progression-free survival was estimated using the Kaplan-Meier method and reported as percentage of participants.
Percent Change From Baseline In Serum Concentrations Of Luteinizing Hormone Week 1 Day 4 (Day 4), Week 5 Day 1 (Day 29), Week 25 Day 1 (Day 169), and Week 49 Day 1 (Day 337) Blood samples were collected from participants for hormonal measurements.
Area Under The Concentration-Time Curve (AUC0-τ) Of Relugolix Predose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hours postdose on Day 1 and Week 2 The AUC0-τ of relugolix was determined for single and repeat doses in subsets of participants from Japan. Single dose PK was assessed on Day 1 following an initial 360 mg dose of relugolix. Repeat dose PK was assessed following repeat dosing of relugolix 120 mg once daily for 2 weeks.
Castration Rate At Week 1 Day 4 Week 1 Day 4 (Day 4) Castration rate was defined as the cumulative probability of testosterone suppression to \< 50 ng/dL. The rate was estimated for each treatment group using the Kaplan-Meier method and reported as percentage of participants.
Confirmed Prostate-specific Antigen (PSA) Response Rate Week 3 Day 1 (Day 15) and Week 5 Day 1 (Day 29) Confirmed PSA response defined as \> 50% reduction in PSA from baseline at Week 3 Day 1 followed with confirmation at Week 5 Day 1.
Castration Rate At Week 3 Day 1 Week 3 Day 1 (Day 15) Castration rate was defined as the cumulative probability of testosterone suppression to \< 50 ng/dL. The rate was estimated for each treatment group using the Kaplan-Meier method and reported as percentage of participants.
Follicle-stimulating Hormone (FSH) Level Week 25 Day 1 (Day 169) To evaluate the effect of relugolix and leuprolide acetate on FSH suppression.
Profound Castration Rate At Week 1 Day 4 (Day 4) At Week 1 Day 4 (Day 4) Castration rate defined as the cumulative probability of testosterone suppression to \< 20 ng/dL. The rate was estimated for each treatment group using the Kaplan-Meier method and reported as percentage of participants.
Change From Baseline In Quality Of Life (QoL) Total Score As Assessed By The Global Health Domain Of The European Organisation Of Research And Treatment Of Cancer (EORTC)-Quality Of Life Questionnaire (QLQ)-C30 Baseline, Week 49 Day 1 (Day 337) The EORTC QLQ-C30 core measurement was used to capture distal outcomes, including physical, social functioning, and overall health-related quality of life. The questionnaire incorporates 30 questions comprising nine multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health and quality of life scale. All raw domain scores are linearly transformed to a 0-100 scale. The global health and quality of life domain is presented. An increase in activity or functioning scores indicates improvement (higher/healthier level of functioning) and a decrease in symptom scores indicates improvement (lower level of symptoms/problems).
Change From Baseline In QoL Total Score For Remaining Domain Scores As Assessed By The EORTC-QLQ-C30 Baseline, Week 49 Day 1 (Day 337) The EORTC QLQ-C30 core measurement was used to capture distal outcomes, including physical, social functioning, and overall health-related quality of life. The questionnaire incorporates 30 questions comprising nine multi-item scales: 5 functional scales (physical, role, cognitive, emotional, and social); 3 symptom scales (fatigue, pain, and nausea and vomiting); and a global health and quality of life scale. All raw domain scores are linearly transformed to a 0-100 scale. All domains except for the global health and quality are presented. An increase in activity or functioning scores indicates improvement (higher/healthier level of functioning) and a decrease in symptom scores indicates improvement (lower level of symptoms/problems).
Change From Baseline In QoL Total Score For Urinary And Bowel Symptoms Domains As Assessed By The EORTC-QLQ-PR25 Baseline, Week 49 Day 1 (Day 337) Subscale assessments of urinary symptoms (9 items) and bowel symptoms (4 items) from the EORTC-QLQ-PR25 25-item prostate cancer module of the EORTC are presented. Questions used 4 point scale (1 'Not at all' to 4 'Very much'). All raw domain scores are linearly transformed to a 0-100 scale. A decrease in symptom scores indicates improvement (lower level of symptoms/problems).
Time To Maximum Observed Plasma Concentration (Tmax) Of Relugolix Predose and 0.5, 1, 2, 4, 6, 8, 12, and 24 hours postdose on Day 1 and Week 2 The Tmax of relugolix was determined for single and repeat doses in subsets of participants from Japan. Single dose PK was assessed on Day 1 following an initial 360 mg dose of relugolix. Repeat dose PK was assessed following repeat dosing of relugolix 120 mg once daily for 2 weeks.
Sustained Profound Castration Rate From Week 25 Day 1 Through Week 49 Day 1 Week 25 Day 1 (Day 169) through Week 49 Day 1 (Day 337) Sustained profound castration rate was defined as the cumulative probability of testosterone suppression to \< 20 ng/dL. The rate was estimated by the Kaplan-Meier method and reported as percentage of participants.
Percent Change From Baseline In Serum Concentrations Of Dihydrotestosterone Week 5 Day 1 (Day 29), Week 25 Day 1 (Day 169), and Week 49 Day 1 (Day 337) Blood samples were collected from participants for hormonal measurements.
Trial Locations
- Locations (149)
Greensboro
🇺🇸Greensboro, North Carolina, United States
Albany
🇺🇸Albany, New York, United States
Syracuse
🇺🇸Syracuse, New York, United States
Camperdown
🇦🇺Camperdown, New South Wales, Australia
Las Vegas
🇺🇸Las Vegas, Nevada, United States
Durham
🇺🇸Durham, North Carolina, United States
San Antonio
🇺🇸San Antonio, Texas, United States
Lanzhou
🇨🇳Lanzhou, China
Linz
🇦🇹Linz, Austria
Strasbourg
🇫🇷Strasbourg, Bas-Rhin, France
Chiba
🇯🇵Chiba, Japan
Amsterdam
🇳🇱Amsterdam, Noord Holland, Netherlands
Nakano-ku
🇯🇵Nakano-ku, Tokyo, Japan
Exeter
🇬🇧Exeter, Devon, United Kingdom
Itabuna
🇧🇷Itabuna, Bahia, Brazil
Quebec
🇨🇦Quebec, Canada
Salvador
🇧🇷Salvador, Bahia, Brazil
Hamilton
🇳🇿Hamilton, New Zealand
Porto Alegre
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Ijuí
🇧🇷Ijuí, Rio Grande Do Sul, Brazil
Passo Fundo
🇧🇷Passo Fundo, Rio Grande Do Sul, Brazil
Shanghai
🇨🇳Shanghai, China
Nashville
🇺🇸Nashville, Tennessee, United States
Orange
🇺🇸Orange, California, United States
Sala
🇸🇰Šaľa, Slovakia
Tokyo
🇯🇵Tokyo, Japan
Goyang-Si
🇰🇷Goyang-si, Gyeonggido, Korea, Republic of
Helsinki
🇫🇮Helsinki, Finland
Tampere
🇫🇮Tampere, Finland
Suzhou
🇨🇳Suzhou, China
Aarhus
🇩🇰Aarhus, Denmark
Milano
🇮🇹Milano, Italy
Turku
🇫🇮Turku, Finland
Meldola
🇮🇹Meldola, Emilia-Romagna, Italy
Braunschweig
🇩🇪Braunschweig, Niedersachsen, Germany
Sumida-ku
🇯🇵Sumida-ku, Tokyo, Japan
Seoul
🇰🇷Seoul, Korea, Republic of
Creteil
🇫🇷Créteil, Val-de-Marne, France
Suita
🇯🇵Suita, Osaka, Japan
Alborg
🇩🇰Aalborg, Denmark
Herlev
🇩🇰Herlev, Denmark
Lyon
🇫🇷Lyon, France
Hangzhou
🇨🇳Hangzhou, China
Vejle
🇩🇰Vejle, Denmark
Pierre Benite
🇫🇷Pierre-Bénite, Rhone, France
Seinajoki
🇫🇮Seinäjoki, Finland
A Coruna
🇪🇸A Coruña, A Coruna, Spain
Gdynia
🇵🇱Gdynia, Pomorskie, Poland
Kosice
🇸🇰Košice, Slovakia
Candiolo
🇮🇹Candiolo, Piemonte, Italy
Orbassano
🇮🇹Orbassano, Piemonte, Italy
Dunedin
🇳🇿Dunedin, New Zealand
Madrid
🇪🇸Madrid, Spain
Munster
🇩🇪Münster, Germany
Cremona
🇮🇹Cremona, Lombardia, Italy
Arezzo
🇮🇹Arezzo, Toscana, Italy
Fukuoka
🇯🇵Fukuoka, Japan
Hiroshima
🇯🇵Hiroshima, Japan
Kita-gun
🇯🇵Kita, Japan
Maebashi
🇯🇵Maebashi, Japan
Nagasaki
🇯🇵Nagasaki, Japan
Christchurch
🇳🇿Christchurch, New Zealand
Daegu
🇰🇷Daegu, Korea, Republic of
Busan
🇰🇷Busan, Korea, Republic of
Kyoto
🇯🇵Kyoto, Japan
Lublin
🇵🇱Lublin, Lubelskie, Poland
Nottingham
🇬🇧Nottingham, United Kingdom
Rhyl
🇬🇧Rhyl, United Kingdom
Trencin
🇸🇰Trenčín, Slovakia
Barcelona
🇪🇸Barcelona, Spain
Valencia
🇪🇸Valencia, Spain
Stockholm
🇸🇪Stockholm, Sodermandlands Ian, Sweden
Malmo
🇸🇪Malmö, Sweden
Salamanca
🇪🇸Salamanca, Spain
Scunthorpe
🇬🇧Scunthorpe, North Lincolnshire, United Kingdom
Taipei
🇨🇳Taipei, Taiwan
Orebro
🇸🇪Örebro, Orebro Ian, Sweden
Denver
🇺🇸Denver, Colorado, United States
Omaha
🇺🇸Omaha, Nebraska, United States
Oklahoma City
🇺🇸Oklahoma City, Oklahoma, United States
Hwasun
🇰🇷Hwasun, Korea, Republic of
Planegg
🇩🇪Planegg, Bayern, Germany
Emmendingen
🇩🇪Emmendingen, Baden-Wurttemberg, Germany
Dresden
🇩🇪Dresden, Germany
Lubeck
🇩🇪Lübeck, Germany
Tauranga
🇳🇿Tauranga, New Zealand
Cincinnati
🇺🇸Cincinnati, Ohio, United States
Pompano Beach
🇺🇸Pompano Beach, Florida, United States
Baltimore
🇺🇸Baltimore, Maryland, United States
Troy
🇺🇸Troy, Michigan, United States
Garden City
🇺🇸Garden City, New York, United States
Plainview
🇺🇸Plainview, New York, United States
Poughkeepsie
🇺🇸Poughkeepsie, New York, United States
Lancaster
🇺🇸Lancaster, Pennsylvania, United States
Middleburg Heights
🇺🇸Middleburg Heights, Ohio, United States
Myrtle Beach
🇺🇸Myrtle Beach, South Carolina, United States
Tweed Heads
🇦🇺Tweed Heads, New South Wales, Australia
Wahroonga
🇦🇺Wahroonga, New South Wales, Australia
Kortrijk
🇧🇪Kortrijk, Belgium
Redcliffe
🇦🇺Redcliffe, Queensland, Australia
Southport
🇦🇺Southport, Queensland, Australia
Teresina
🇧🇷Teresina, Piauí, Brazil
Natal
🇧🇷Natal, Rio Grande Do Norte, Brazil
Changchun
🇨🇳Chang chun, Jilin, China
Joinville
🇧🇷Joinville, Santa Catarina, Brazil
Curitiba
🇧🇷Curitiba, Brazil
São José Do Rio Preto
🇧🇷São José Do Rio Preto, Sao Paulo, Brazil
Calgary
🇨🇦Calgary, Alberta, Canada
Halifax
🇨🇦Halifax, Nova Scotia, Canada
Vancouver
🇨🇦Vancouver, British Columbia, Canada
Montreal
🇨🇦Montréal, Quebec, Canada
London
🇨🇦London, Ontario, Canada
Nanjing
🇨🇳Nanjing, Jiangsu, China
Beijing
🇨🇳Beijing, China
Taiyuan
🇨🇳Taiyuan, Shanxi, China
Beijing Shi
🇨🇳Beijing, China
Chongqing
🇨🇳Chongqing, China
Nanchang
🇨🇳Nanchang, China
Uppsala
🇸🇪Uppsala, Uppsala Lan, Sweden
Sneek
🇳🇱Sneek, Netherlands
Katowice
🇵🇱Katowice, Poland
Brick
🇺🇸Brick, New Jersey, United States
Brussels
🇧🇪Brussels, Belgium
Bratislava
🇸🇰Bratislava, Slovakia
Poprad
🇸🇰Poprad, Slovakia
Gent
🇧🇪Gent, Oost-Vlaanderen, Belgium
Yokohama
🇯🇵Yokohama, Kanagawa, Japan
Osaka
🇯🇵Osaka, Japan
Sapporo
🇯🇵Sapporo, Japan
Tucson
🇺🇸Tucson, Arizona, United States
Bunkyō-Ku
🇯🇵Bunkyō-Ku, Tokyo, Japan
Ube
🇯🇵Ube, Japan
Eindhoven
🇳🇱Eindhoven, Noord Brabant, Netherlands
Nitra
🇸🇰Nitra, Slovakia
Presov
🇸🇰Prešov, Slovakia
Sherbrooke
🇨🇦Sherbrooke, Quebec, Canada
Kanazawa-shi
🇯🇵Kanazawa-shi, Isikawa, Japan
Sendai
🇯🇵Sendai, Miyagi, Japan
Osaka-sayama
🇯🇵Ōsaka-sayama, Osaka, Japan
Siedlce
🇵🇱Siedlce, Mazowieckie, Poland
Kaohsiung City
🇨🇳Kaohsiung City, Taiwan
Rome
🇮🇹Rome, Lazio, Italy
Warszawa
🇵🇱Warszawa, Mazowieckie, Poland
Martin
🇸🇰Martin, Slovakia
Oviedo
🇪🇸Oviedo, Asturias, Spain
Des Moines
🇺🇸Des Moines, Iowa, United States
Wichita
🇺🇸Wichita, Kansas, United States
Albuquerque
🇺🇸Albuquerque, New Mexico, United States
Jeffersonville
🇺🇸Jeffersonville, Indiana, United States